Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alphamab Oncology ( (HK:9966) ) has issued an announcement.
Alphamab Oncology announced an increase in shareholding by its directors and senior management, who purchased 900,000 shares between July 14 and July 16, 2025, reflecting their confidence in the company’s growth prospects. Additionally, CEO Dr. Xu Ting exercised 9,005,890 options under the company’s Pre-IPO Share Option Plan I, further demonstrating strong belief in the company’s long-term investment value. These actions comply with relevant laws and regulations, maintaining a sufficient public float of shares.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company based in the Cayman Islands, focusing on the development of innovative oncology therapies. The company is listed on the Hong Kong Stock Exchange and is involved in the research and development of cancer treatments.
Average Trading Volume: 3,894,113
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.51B
See more insights into 9966 stock on TipRanks’ Stock Analysis page.